Latest Singapore News

iCandy Interactive confirms its removal from the ASX on 1 April 2026, shifting focus to a potential NYSE American listing for its key asset, Lemon Sky Studios.

Electro Optic Systems secures two significant US contracts worth US$12 million for advanced Remote Weapon Systems, while progressing a conditional US$80 million Korean High Energy Laser contract with potential manufacturing shifts.

Firebrick Pharma has successfully secured $1.5 million through a strategic placement, positioning itself to accelerate business development and launch new products in key markets.

Fatfish Group has revealed improper conduct by a former service provider that delayed its 2024 financial reporting, while outlining ongoing legal actions and a strategy to relist on the ASX within four months.

Osteopore Limited has drawn down an additional $250,000 on the second tranche of its redeemable convertible notes, continuing its strategic funding partnership with Advance Opportunities Fund. This incremental funding supports the company’s ongoing business and future growth initiatives.

Reach Resources Limited has announced a pro-rata entitlement issue aiming to raise up to $3.15 million to fund exploration and working capital, with key directors and the CEO committing to participate.

Tuas Limited has reported a robust first half for FY26, with significant revenue and profit growth driven by expanding mobile and broadband subscribers, alongside progress on its strategic M1 acquisition.

Clover Corporation has reported a robust first half for FY26, with revenue climbing 17% and margins expanding significantly, underpinning a confident revenue forecast for the full year.

Commonwealth Bank of Australia has updated its 2026 interim dividend details, confirming a fully franked payout of AUD 2.35 per share and setting the Dividend Reinvestment Plan price at AUD 174.47 with no discount.

CLINUVEL Pharmaceuticals reports record first-half profits and confirms CEO Philippe Wolgen’s leadership through a pivotal growth phase, prioritising its vitiligo program and Nasdaq ambitions.

BPH Global is expanding its seaweed biomass research to develop renewable biofuels like biohydrogen and biocrude, aiming to carve out a sustainable alternative to fossil fuels in energy and transport sectors.

Osteopore Limited has secured non-exclusive distribution rights for an injectable regenerative bone filler across Southeast Asia, marking a strategic expansion of its orthopaedic product portfolio and opening new revenue channels.